MYQ completes $5M cap raise: adds a further $1.5M into the kitty

|

Published 16-OCT-2020 10:20 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

MyFiziq (ASX: MYQ) announced today that it has completed a substantially oversubscribed $5M capital raising.

It is one of the highlights of a strong week for funding and payments made to the company, putting MYQ in the best financial position it has been in for years.

“The week has closed out on a very positive note, with the capital raising oversubscribe placing $5,000,000 into the MYQ account, this was further enhanced with inflows from our US NASDAQ initiative funding, Government R&D reimbursements, a license payment from BCT and partner revenues. This totalled a further $1,504,977 of inflows to the company. I am pleased to say the company is in the best financial position it has been in for the past few years, with ample capital to accelerate growth and execute on our NASDAQ initiatives,” MYQ CEO Vlado Bosanac said.

MyFiziq has developed and patented a proprietary dimensioning technology that enables its users to privately and accurately check, track, and assess their dimensions using only a smartphone.

The app aims to assist MYQ’s partners in empowering their consumers to lead a healthier life, by understanding the risks associated with their physical condition and tracking the changes they are experiencing through training, dieting, or under medical regimes. Additional uses include the ability to be correctly sized for a garment when shopping online. The MyFiziq technology delivers this seamlessly, privately, and cost-effectively in under one minute.

A full understanding of how the tech works and what MYQ does for clients and consumers can be found in the following WiseOwl research report.

Breaking down the numbers, MYQ received a payment of US$375,000 (A$523,000) by way of convertible note subscription deed with iConcept Global Growth Fund.

The funds have to do with the Convertible Note funding agreement with Asia Cornerstone Asset Management (ACAM), who is assisting MYQ with its NASSDAQ listing.

MYQ was to receive a total of US$1.5M in 4 tranches, with an initial US$1.1M already received from ACAM. Under a deed of variation, ACAM has set aside the final payment allowing IGGF to take the balance US$375,000 which has now been paid.

As we reported in June, ACAM played a significant role in the introduction of advisors, US law firms and bankers through its extensive network in the US, with regard to MYQ’s potential dual listing.

Further funds this week have come from a license payment from Body Composition Technologies Pte Ltd (BCT) of $121,794 and partner revenues of $70,706.

BCT is working with MYQ to develop and commercialise the MyFiziq application for the medical and insurance sectors, allowing an up-to-date record of the patient’s body shape and body composition to be directly available to the participant and to their medical practitioner’s or insurer’s records.

Earlier in the year, BCT deployed its first commercial partner in Hong Kong with The CareVoice.

MYQ also received the largest R&D funding reimbursement to date, totalling $784,412.

The increased R&D payment is a direct outcome of the deep expansion of capabilities MYQ has delivered over the past year.

The new functionality and added performance of the application is an ongoing requirement MYQ’s development team, who will continually be involved to ensure the technology is best in class.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X